Difference between revisions of "Myeloid Neoplasms with Germline Predisposition"
| [unchecked revision] | [unchecked revision] |
| Line 34: | Line 34: | ||
==Additional Information== | ==Additional Information== | ||
| − | *''ANKRD26 (OMIM: 610855)'' has been associated with thrombocytopenia 2 ( | + | *''ANKRD26 (OMIM: 610855)'' has been associated with thrombocytopenia 2 ([https://www.omim.org/entry/188000 OMIM: 188000)] |
| − | *''CEBPA (OMIM: 116897)'' has been associated with acute myeloid leukemia ( | + | *''CEBPA (OMIM: 116897)'' has been associated with acute myeloid leukemia ([https://www.omim.org/entry/601626 OMIM: 601626]) |
*''DDX41'' ''(OMIM: 608170)'' has been associated with susceptibility to multiple types of familial myeloproliferative/lymphoproliferative neoplasms (OMIM: 616871, <nowiki>https://www.omim.org/entry/616871</nowiki>). | *''DDX41'' ''(OMIM: 608170)'' has been associated with susceptibility to multiple types of familial myeloproliferative/lymphoproliferative neoplasms (OMIM: 616871, <nowiki>https://www.omim.org/entry/616871</nowiki>). | ||
*''ETV6'' ''(OMIM: 600618)'' has been associated with thrombocytopenia 5 (OMIM: 616216, <nowiki>https://www.omim.org/entry/616216</nowiki>). | *''ETV6'' ''(OMIM: 600618)'' has been associated with thrombocytopenia 5 (OMIM: 616216, <nowiki>https://www.omim.org/entry/616216</nowiki>). | ||
Revision as of 11:47, 7 January 2021
Primary Author(s)*
Jialing Huang, MD, PhD; Ying Zou, MD, PHD, FACMG
Johns Hopkins University, Baltimore, MD
General Disease Overview / Description of Cancer Category
Increasingly performed high throughput molecular assays enable deeper and comprehensive understanding of genetic changes in neoplasms, which reflect tumor biology and behavior. Simultaneously, many underlying germline mutations of genes accounting for solid and hematopoietic neoplasms have been progressively identified. These patients usually have an early onset of myeloid malignancies (younger patients), evidence of disease anticipation, multiple cases of myeloid malignancies with multiple generations in a pedigree, and/or life-long defects in platelet number and dysfunction, and/or a personal history of multiple cancers. It is known that familial myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) are driven by genomic alterations such as mutations in genes encoding transcription factors (GATA-2, RUNX1, ETV6, and CEBPα) involved in hematopoietic stem and progenitor cell (HSPC) development and differentiation. On this basis, a group of hereditary myeloid disorder (HMD) have been incorporated in the WHO 2016 classification of myeloid neoplasms and acute leukemia [1].
There are three categories of genetic predisposed myeloid malignancies:
(1) Familial myelodysplastic syndrome and acute myeloid leukemia caused by germline mutations in ANKRD26, CEBPA, DDX41, ETV6, GATA2, RUNX1, MSH6, DDX41, SAMD9, SAMD9L and SRP72 genes. About 5% to 10% of patients with MDS and/or AML carry germline mutations in these genes.
(2) Familial cancer syndromes associated with increased risk of multiple types of malignancies in addition to myelodysplasia (MDS) and acute myeloid leukemia (AML), such as Li-Fraumeni syndrome (TP53 gene), Bloom syndrome (BLM gene), and constitutional mismatch repair deficiency (CMMRD; also known as biallelic mismatch repair deficiency (BMMRD)), neurofibromatosis type I, Nijmegen breakage syndrome (NBS) and Noonan syndrome.
(3) Familial pediatric inherited bone marrow failure syndromes, including Fanconi anemia (FA), dyskeratosis congenital (DC), severe congenital neutropenia (SCN), Shwachman-Diamond syndrome (SDS), MIRAGE syndrome and Diamond Blackfan anemia (DBA). These syndromes are caused by mutations in more than one gene, except for SDS and MIRAGE syndrome, which are caused by SDBS and SMAD9 gene mutation, respectively.
The patients with pathogenic mutations of these susceptibility genes usually have characteristic clinical features and should be managed differently from those sporadic cases with a multidisciplinary team. Detailed family and medical history and appropriate genetic testing and counseling are important for recognition and detection of these conditions, and close monitoring is vital for early identification of malignant transformation.
WHO Classification Pages (Includes Links to Content)
- Acute Myeloid Leukaemia with Germline CEBPA Mutation
- Myeloid Neoplasms with Germline DDX41 Mutation
- Myeloid Neoplasms with Germline RUNX1 Mutation
- Myeloid Neoplasms with Germline ANKRD26 Mutation
- Myeloid Neoplasms with Germline ETV6 Mutation
- Myeloid Neoplasms with Germline GATA2 Mutation
Other Related Pages (Includes Links to Content)
Put your links here (use "Link" icon at top of page
Additional Information
- ANKRD26 (OMIM: 610855) has been associated with thrombocytopenia 2 (OMIM: 188000)
- CEBPA (OMIM: 116897) has been associated with acute myeloid leukemia (OMIM: 601626)
- DDX41 (OMIM: 608170) has been associated with susceptibility to multiple types of familial myeloproliferative/lymphoproliferative neoplasms (OMIM: 616871, https://www.omim.org/entry/616871).
- ETV6 (OMIM: 600618) has been associated with thrombocytopenia 5 (OMIM: 616216, https://www.omim.org/entry/616216).
- GATA2 (OMIM: 137295) has been associated with susceptibility to acute myeloid leukemia (OMIM: 601626, https://www.omim.org/entry/601626).
- RUNX1 (OMIM: 151385) has been associated with acute myeloid leukemia (OMIM: 601626) and familial platelet disorder with associated myeloid malignancy (OMIM: 601399, https://www.omim.org/entry/601399).
- DDX41 (OMIM: 608170) has been associated with susceptibility to multiple types of familial myeloproliferative/lymphoproliferative neoplasms (OMIM: 616871, https://www.omim.org/entry/616871).
- SAMD9 (OMIM: 610456) has been associated with Myelodysplasia, Infection, Restriction of growth, Adrenal hypoplasia, Genital phenotypes, and Enteropathy (MIRAGE syndrome, OMIM: 617053, https://www.omim.org/entry/617053).
- SAMD9L (OMIM: 611170) has been associated with ataxia-pancytopenia syndrome, or myelocerebellar disorder, ataxia-pancytopenia syndrome (OMIM: 159550, https://www.omim.org/entry/159550).
- SRP72 (OMIM: 602122) has been associated with bone marrow failure syndrome 1 (OMIM: 614675, https://www.omim.org/entry/614675).
- TP53 (OMIM: 191170) has been associated with Li-Fraumeni syndrome (OMIM: 151623, https://www.omim.org/entry/151623).
- BLM (OMIM: 604610) has been associated with Bloom syndrome (OMIM: 210900, https://www.omim.org/entry/210900).
- Constitutional mismatch repair deficiency (OMIM: 276300, https://www.omim.org/entry/276300)
- Neurofibromatosis type I (NF1, OMIM: 162200, https://www.omim.org/entry/162200)
- Nijmegen breakage syndrome (NBS, OMIM: 251260, https://www.omim.org/entry/251260)
- Noonan syndrome (please see Genetic heterogeneity of Noonan syndrome at https://www.omim.org/entry/163950
- Fanconi anemia (FA, please see Genetic heterogeneity of Fanconi anemia at https://www.omim.org/entry/227650),
- Dyskeratosis congenital (DC, please see Genetic heterogeneity of dyskeratosis congenital at https://www.omim.org/entry/127550).
- Severe congenital neutropenia (SCN, please see Genetic heterogeneity of severe congenital neutropenia at https://www.omim.org/entry/202700)
- Shwachman-Diamond syndrome 1 (SDS1, OMIM: 260400, https://www.omim.org/entry/260400) and Shwachman-Diamond syndrome 2 (SDS2, OMIM: 617941, https://www.omim.org/entry/617941)
- Diamond Blackfan anemia (DBA, please see Genetic heterogeneity of Diamond Blackfan anemia at https://www.omim.org/entry/105650).
References
- ↑ Peterson LC, et al., (2017). Myeloid neoplasms with germline predisposition, in World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th edition. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Arber DA, Hasserjian RP, Le Beau MM, Orazi A, and Siebert R, Editors. IARC Press: Lyon, France, p122-128.
Notes
*Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage). Additional global feedback or concerns are also welcome.